Selective action of metoprolol to attenuate regadenoson-induced tachycardia in conscious dogs

Journal of Nuclear Cardiology

Volumn 19, Issue 1, 2012, Pages 109-117

  Zhao, Gong ^a   Zhang, Suhua ^b   Shryock, John C ^a   Xu, Xiaobin ^b   Ochoa, Manuel ^b   Hintze, Thomas H ^b   Belardinelli, Luiz ^a  

^a Gilead Sciences Palo Alto ^*  (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Conscious dogs; Coronary vasodilation; Heart rate; Metoprolol; Regadenoson

Indexed keywords

METOPROLOL; REGADENOSON; ANTIARRHYTHMIC AGENT; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; DOG; DRUG BLOOD LEVEL; HEART HEMODYNAMICS; HEART LEFT VENTRICLE CONTRACTILITY; HEART RATE; MALE; NONHUMAN; PRIORITY JOURNAL; TACHYCARDIA; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; DOGS; HEART RATE; MALE; METOPROLOL; PURINES; PYRAZOLES; TACHYCARDIA; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84861487203     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-011-9481-x     Document Type: Article

References (17)

1. Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007;14:645-58. (Pubitemid 47355078)
2. Jaroudi WA, Iskandrian AE. Regadenoson: A new myocardial stress agent. J Am Coll Cardiol 2009;54:1123-30.
3. Tejani FH, Thompson RC, Iskandrian AE, McNutt BE, Franks B. Effects of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: Rationale and design of a prospective, randomized, multicenter study. J Nucl Cardiol 2011;18:73-81.
4. Cerqueira MD. The future of pharmacologic stress: Selective A2A adenosine receptor. Am J Cardiol 2004;94:33D-42D. (Pubitemid 38917189)
5. Hendel RC, Bateman TM, Cerqueira MD, Iskandrian AE, Leppo JA, Blackburn B, et al. Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single- photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol 2005;46:2069-75. (Pubitemid 41713594)
6. Lieu H, Shryock JC, von-Mering GO, Gordi T, Blackburn B, Olmsted AW, et al. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol 2007;14:514-20. (Pubitemid 47163555)
7. Trochu JN, Zhao G, Post H, Xu X, Belardinelli L, Belloni F, et al. Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: Potential for use in myocardial perfusion imaging. J Cardiovasc Pharmacol 2003;41:132-9. (Pubitemid 36015065)
8. Zhao G, Linke A, Xu X, Ochoa M, Belloni F, Belardinelli L, et al. Comparative profile of vasodilation by CVT-3146, a novel A2A receptor agonist, and adenosine in conscious dogs. J Pharmacol Exp Ther 2003;307:182-9. (Pubitemid 37151905)
9. Zhao G, Messina E, Xu X, Ochoa M, Sun HL, Leung K, et al. Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist. J Cardiovasc Pharmacol 2007;49:369-75. (Pubitemid 47000311)
10. Biaggioni I, Killian TJ, Mosqueda-Garcia R, Robertson RM, Robertson D. Adenosine increases sympathetic nerve traffic in humans. Circulation 1991;83:1668-75.
11. Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther 2006;316:695-702. (Pubitemid 43130996)
12. Zhao G, Serpillon S, Shryock J, Messina E, Xu X, Ochoa M, et al. Regadenoson, a novel pharmacologic stress agent for use in myocardial perfusion imaging, does not have a direct effect on the QT-interval in conscious dogs. J Cardiovasc Pharmacol 2008; 52:467-73.
13. Mekkaoui C, Jadbabale F, Dione DP, Meoli DF, Purushothaman K, Belardinelli L, et al. Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-sestaMIBI biodistribution and kinetics. J Am Coll Cardiol Cardiovasc Imaging 2009;2:1198-208.
14. Kerins DM, Robertson RM, Robertson D. Drugs used for the treatment of myocardial ischemia. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman & Gilman's the pharmacological basis of therapeutics 10th ed. New York, NY: McGraw-Hill; 2001. p. 843-70.
15. Vatner SF, Hintze TH, Macho P. Regulation of large coronary arteries by b-adrenergic mechanisms in the conscious dog. Circ Res 1982;51:56-66. (Pubitemid 12092390)
16. Vatner SF, Hintze TH. Mechanism of constriction of large coronary arteries by b-adrenergic receptor blockade. Circ Res 1983;53:389-400. (Pubitemid 13012421)
17. Gao Z, Li Z, Baker SP, Lasley RD, Mayer S, Elzein E, et al. Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: Inverse relationship between affinity and duration of action of A2A agonists. J Pharmacol Exp Ther 2001;298: 209-18. (Pubitemid 32574529)